Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive MedicationsGastroenterology, 2021
- Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort studyGut, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximabGut, 2021
- SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meetingGut, 2021
- Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccinesVaccine, 2005